Yann Mazabraud is VP at RHYTHM PHARMACEUTICALS, INC. (RYTM). They have made 2 open-market trades across 1 company since 2022, most recently 2026-08-12.
CIK 0001774702
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RYTM | 55,655 | $4.8M |
Shares reported on the most recent Form 4, priced at the 2026-08-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RYTM | SELL · 10b5-1 | 2026-08-12 | 2026-08-14 | $116.15 | $6.6M | -3.6% | -11.7% | — |
| RYTM | SELL · 10b5-1 | 2025-04-29 | 2025-05-01 | $65.08 | $878K | -11.3% | -0.6% | +32.2% |
| RYTM | SELL · 10b5-1 | 2025-04-08 | 2025-04-10 | $60.98 | $2.2M | +3.6% | +2.1% | +54.1% |
| RYTM | SELL · 10b5-1 | 2025-03-14 | 2025-03-18 | $51.48 | $7.7M | +4.9% | +18.2% | +19.4% |
| RYTM | SELL | 2024-03-19 | 2024-03-19 | $39.22 | $628K | +9.9% | -1.9% | +6.0% |
| RYTM | SELL | 2024-02-12 | 2024-02-13 | $51.02 | $211K | -7.7% | -20.0% | -19.6% |
| RYTM | SELL · 10b5-1 | 2023-02-14 | 2023-02-16 | $27.03 | $32K | +1.2% | -30.7% | -35.5% |
| RYTM | SELL · 10b5-1 | 2023-02-09 | 2023-02-14 | $27.51 | $43K | -8.7% | -33.2% | -37.5% |
| RYTM | SELL · 10b5-1 | 2023-02-09 | 2023-02-13 | $27.66 | $43K | -9.8% | -32.2% | -37.1% |
| RYTM | SELL · 10b5-1 | 2022-02-15 | 2022-02-15 | $6.10 | $6K | +13.7% | +60.6% | -51.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.